NCT05523596View on ClinicalTrials.gov

A Phase 1 Study of the Safety and Tolerability of ICM20 in Adults

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

December 20, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

March 31, 2027

Conditions
Safety Issues
Interventions
DRUG

ICM20

small molecules

DRUG

Benznidazole

small molecule

Trial Locations (3)

21061

Parkway Medical, Glen Burnie

22044

Culmore Clinic, Falls Church

77030

Baylor College of Medicine, Houston

Sponsors
All Listed Sponsors
lead

IC-MedTech Corporation

INDUSTRY